Irinotecan HCl Trihydrate

Catalog No.S2217 Synonyms: CPT-11 HCl Trihydrate

Irinotecan HCl Trihydrate Chemical Structure

Molecular Weight(MW): 677.18

Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 70 In stock
USD 210 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 30 Publications

Purity & Quality Control

Choose Selective Topoisomerase Inhibitors

Biological Activity

Description Irinotecan prevents DNA from unwinding by inhibition of topoisomerase 1.
Features Irinotecan is a prodrug that is used to treat metastatic colorectal cancer.
Targets
Topo I [1]
In vitro

Irinotecan is activated to SN-38 by carboxylesterases to become able to interact with its target, topoisomerase I. Irinotecan induces similar amounts of cleavable complexes at its IC50 in LoVo cells and HT-29 cell lines. SN-38 induces a concentration-dependent formation of cleavable complexes, which is not significantly different in LoVo cells and HT-29 cell lines. Cell accumulation of Irinotecan is markedly different, reaching consistently higher levels in HT-29 cells than in LoVo cells. [1] The lactone E-ring of Irinotecan and SN-38 hydrolyses reversibly in aqueous solutions, and the interconversion between the lactone and carboxylate forms is dependent on pH and temperature. Liver is primarily responsible for the activation of Irinotecan to SN-38. At equal concentrations of Irinotecan and SN-38 glucuronide, the rate of beta-glucuronidase-mediated SN-38 production is higher than that formed from Irinotecan in both tumour and normal tissue. [2] Irinotecan is also converted to SN-38 in intestines, plasma and tumor tissues. [3] Irinotecan is significantly more active in SCLC than in NSCLC cell lines, whereas no significant difference between histological types is observed with SN-38. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse bone marrow cell M{exSGN6fG:2b4jpZ4l1gSCjc4PhfS=> MnK0R5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgZo9v\SCvYYLyc5ch[2WubDDifUBETlVvR12gZZN{[XlwIFnDOVA:OC5yMEGg{txO M{XIOlIyOzRzNke0
PC3 cells MnrwR5l1d3SxeHnjbZR6KGG|c3H5 NG\0RW04OiCq M3jpVWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHBEOyClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6wOEDPxE1? MYCyNVM1OTZ5NB?=
A375 cells MWDDfZRwfG:6aXPpeJkh[XO|YYm= M3e4e|czKGh? MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBN|c2KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeT6gTWM2OD1yLkC0JO69VQ>? MmnBNlE{PDF4N{S=
LNCAP cells Ml3zR5l1d3SxeHnjbZR6KGG|c3H5 MnTiO|IhcA>? NVO2UplPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE6FQWCgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NiCLQ{WwQVAvODlizszN Mn[zNlE{PDF4N{S=
MESSA cells M33TSmN6fG:2b4jpZ4l1gSCjc4PhfS=> MX23NkBp NFrpO29EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTVOVQTDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4xOSEQvF2= M1X3SVIyOzRzNke0
H460 cells Mlq0R5l1d3SxeHnjbZR6KGG|c3H5 NWDLc4hCPzJiaB?= NUXxZYlPS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4xOTVizszN MWmyNVM1OTZ5NB?=
MES-SA/Dx5 cells MlTYR5l1d3SxeHnjbZR6KGG|c3H5 NFXJPZc4OiCq M13wOmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1GWy2VQT;EfFUh[2WubIOgc5ZmemW6cILld5NqdmdiTVTSNUBi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6wNlIh|ryP MUKyNVM1OTZ5NB?=
H69 cells M37oPGN6fG:2b4jpZ4l1gSCjc4PhfS=> NV\HSWVGPzJiaB?= MX7DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIOlkh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IHHsZY1ieiCkbIXlJIF{e2G7LjDJR|UxRTBwMEKyJO69VQ>? M33DVlIyOzRzNke0
IGROV1 cells MorOR5l1d3SxeHnjbZR6KGG|c3H5 M3PnSFczKGh? MWHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDJS3JQXjFiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JIFt[W2jcjDicJVmKGG|c3H5MkBKSzVyPUCuNFMh|ryP MnvnNlE{PDF4N{S=
SK-MEL-2 cells NHnt[VVEgXSxdH;4bYNqfHliYYPzZZk> Mk\GO|IhcA>? Mof5R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV2suVUWOLUKgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NiCLQ{WwQVAvOSEQvF2= Mlm5NlE{PDF4N{S=
MALME-3M cells MkXrR5l1d3SxeHnjbZR6KGG|c3H5 M3HmNFczKGh? M2PXc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1CVE2HLUPNJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigS5iSVO1NF0xNjJizszN M4nSPVIyOzRzNke0
DU145 cells NGrLR4JEgXSxdH;4bYNqfHliYYPzZZk> NFfWZpM4OiCq MWXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6yJO69VQ>? M3zTSlIyOzRzNke0
HT-29 cells MVTDfZRwfG:6aXPpeJkh[XO|YYm= NWjNVGI4PzJiaB?= MVHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmuJGlEPTB;MD6yNkDPxE1? MViyNVM1OTZ5NB?=
H69AR cells NIW0[GhEgXSxdH;4bYNqfHliYYPzZZk> M{PzbVczKGh? MnHPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFY6SVJiY3XscJMhd3[ncnX4dJJme3OrbnegUWRTOSCjZoTldkA4OiCqcoOgZpkh[WyjbXHyJIJtfWViYYPzZZkvKEmFNUC9NE4zPSEQvF2= MWeyNVM1OTZ5NB?=
MCF7 cells NWnYXY5GS3m2b4TvfIlkcXS7IHHzd4F6 M{P6TlI1KGh? MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCjZoTldkAzPCCqcoOgZpkhVVSVIHHzd4F6NiCLQ{WwQVAvPSEQvF2= Ml7sNlY5PDFzNki=
HCT116 M2jUfWZ2dmO2aX;uJIF{e2G7 M1PXWGNwdXCxdX7kJJdieyC2ZYP0[YQhcW5idnn0do8h\m:{IHP5eI91d3irY3n0fUBi\2GrboP0JGhEXDFzNjygbJVu[W5iY3;sc44h[2GwY3XyJINmdGy|IDj0ZZhwdC2{ZYPpd5RidnRrIHH0JIEh\HK3ZzDjc45k\W62cnH0bY9vKHC{b3T1Z4lv\yB3MDWgbY5pcWKrdHnvckBw\iClb3zvcpkh\m:{bXH0bY9vNiCLQ{WwQVAvPTRizszN NUjiWXFLOTF7NkWzOlI>
RPMI8402 NUD5cIxuS3m2b4TvfIlkcXS7IHHzd4F6 MmDKOEBl[Xm| M2m3[mN6fG:2b4jpZ{Bi[3Srdnn0fUBi\2GrboP0JIh2dWGwIHz5cZBpd2KuYYP0JJR2dW:{IHPlcIwhdGmwZTDSVG1KQDRyMjDh[pRmeiB2IHThfZMhd2ZidILlZZRu\W62LjDJR|UxRTBwNUeg{txO MWCxNlc1Pzd7OB?=
KB3-1 cells MmjOR5l1d3SxeHnjbZR6KGG|c3H5 NGXSd5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMSjNvMTDj[YxteyCkeTDNWHQhdWW2aH;kMkBKSzVyPUCuOlgh|ryP MYCxPFc4OTl|MB?=
PC3 cells M{jKWnBzd2yrZnXyZZRqd25iYYPzZZk> M3fiWlczKGh? Mk\URY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdHWuYYKgSG5CKGOxboTlcpQh[W[2ZYKgO|IhcHK|IHL5JGN6WVWDTmSgUmYh\my3b4Lld4NmdmOnIHHzd4F6NiCLQ{WwQVAvQCEQvF2= MnXlNlY4OzF|MEC=
A549 cells MWLDfZRwfG:6aXPpeJkh[XO|YYm= MUSyOEBp M4Tze2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[XO|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINmdGxidnnhZoltcXS7IHHmeIVzKDJ2IHjyd{BjgSCPVGOgZZN{[XlwIFnDOVA:OC56IN88US=> NHLh[20zPjh2MUG2PC=>
MCF7 cells MlrwVJJwdGmoZYLheIlwdiCjc4PhfS=> Mlz5PVYhcA>? MXnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdHWuYYKgSG5CKGOxboTlcpQh[W[2ZYKgPVYhcHK|IHL5JGN6WVWDTmSgUmYh\my3b4Lld4NmdmOnIHHzd4F6NiCLQ{WwQVAvQSEQvF2= MWmyOlc{OTNyMB?=
HepG2 cells M4LIV2N6fG:2b4jpZ4l1gSCjc4PhfS=> M{jHVlI1KGh? MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDI[ZBIOiClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhOjRiaILzJIJ6KE2WUzDhd5NigS5iSVO1NF0xNjlizszN NHTlTmszPjh2MUG2PC=>
MDA-MB-435 cells M{jmPWN6fG:2b4jpZ4l1gSCjc4PhfS=> MVq3NkBp NX\3WJhmS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUSDLV3CMVQ{PSClZXzsd{Bi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MkBKSzVyPUGuNVQh|ryP MYqyNFM4OTF6Mx?=
LS174T cells NWr1epF5S3m2b4TvfIlkcXS7IHHzd4F6 NFHXdFI6PiCq MoTpR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUHMyPzSWIHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZkvKEmFNUC9NU4yPiEQvF2= M2nhflE5PTF|OUe2
T84 cells MX\Qdo9tcW[ncnH0bY9vKGG|c3H5 M3HT[Fk3KGh? MXPBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFR6NDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtfWyjcjDEUmEh[2:wdHXueEBi\nSncjC5OkBpenNiYomgR5lSXUGQVDDOSkBndHWxcnXzZ4Vv[2ViYYPzZZkvKEmFNUC9NU4zKM7:TR?= MVOyOlc{OTNyMB?=
SW480 cells M3:1RmN6fG:2b4jpZ4l1gSCjc4PhfS=> M2n4bFI1KGh? M4HsV2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNYPDhyIHPlcIx{KGG|c3Xzd4VlKGG|IILl[JVkfGmxbjDpckBk\WyuII\pZYJqdGm2eTDh[pRmeiB{NDDodpMh[nliTWTTJIF{e2G7LjDJR|UxRTFwNDFOwG0> NFvaUXkzPjh2MUG2PC=>
K562 cells NVTWRoRVWHKxbHnm[ZJifGmxbjDhd5NigQ>? NFrwbG04OiCq MV3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPzJiaILzMkBKSzVyPUGuPUDPxE1? NXflS45mOjV2MkCxO|U>
HT-29 cells M1;EUnBzd2yrZnXyZZRqd25iYYPzZZk> MU[3NkBp Mm\hRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCKVD2yPUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyudXzhdkBFVkFiY3;ueIVvfCCjZoTldkA4OiCqcoOgZpkhS3mTVVHOWEBPTiCobIXvdoV{[2WwY3WgZZN{[XlwIFnDOVA:OS57IN88US=> MofHNlY4OzF|MEC=
HCT116 cells Ml;XVJJwdGmoZYLheIlwdiCjc4PhfS=> M1y0SlI1NTd{IHi= M2XsT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEK0JJRwKDd{IHjyd{BjgSCVUlKgZZN{[XlwIFnDOVA:OiEQvF2= MmHrNlY2QTV6N{W=
Hep3B cells MnfmVJJwdGmoZYLheIlwdiCjc4PhfS=> NWLmNms2PzJiaB?= NEfYUWJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldFNDKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDYWHQh[XO|YYmuJGlEPTB;ND63N{DPxE1? NHzCfIkyQTd7Nkm1Oi=>
Hep3B cells M3X0TGdzd3e2aDDpcohq[mm2b36gZZN{[Xl? MYm3NkBp MXjHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDI[ZA{SiClZXzsd{Bi\nSncjC3NkBpenNiYomgXHRVKGG|c3H5MkBKSzVyPUSuO|Mh|ryP NEPybm4zOjB5OUK1OC=>
LoVo cells NEWwc4VEgXSxdH;4bYNqfHliYYPzZZk> NFPlN4Q4OiCq M4[4cWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfU4hUUN3ME20Mlk6KM7:TR?= M3mxN|IxOzdzMUiz
KBH5.0 cells MkPNR5l1d3SxeHnjbZR6KGG|c3H5 NYLkN|ZqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KKNT6wJINmdGy|IHL5JG1VXCCvZYToc4QvKEmFNUC9O{41KM7:TR?= MlHHNVg4PzF7M{C=
H3347 cells MlL4R5l1d3SxeHnjbZR6KGG|c3H5 NVz4cHhqPzJiaB?= M4LSO2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGg{OzR5IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCDbHHtZZIhSmy3ZTDhd5NigS5iSVO1NF04NjV|IN88US=> NFrZb4ozPDV6M{O1OS=>
HCT15 cells M2XjZnBzd2yrZnXyZZRqd25iYYPzZZk> M1jJWVI1NTd{IHi= NIHubXFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFE2KGOnbHzzJIFnfGW{IEK0JJRwKDd{IHjyd{BjgSCVUlKgZZN{[XlwIFnDOVA:QC53IN88US=> NGTGcZMzPjV7NUi3OS=>

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
AMPK / p-AMPK / mTOR / p-mTOR / p70S6K / p-p70S6K; 

PubMed: 25973791     


Western blot showing the protein levels of AMPK, p-AMPK, mTOR, p-mTOR, p70S6K, and p-p70S6K in LoVo and LoVo-R8 with or without irinotecan. 

NFκB p65 / phospho-NFκB p65 / NFκB p50 / IκBα / p27Kip1; 

PubMed: 22206574     


For Western blot analysis (B), cytoplasmic proteins were analyzed using antibodies against NFκB p65 and p50, phospho-NFκB p65, IκBα and p27Kip1. In the presence of irinotecan, there was a loss of cytoplasmic NF-κBp65, but in the presence of sorafenib, this loss was greatly reduced, corresponding to a decrease in phosphorylation of NF-κBp65. In addition, compared to treatment with sorafenib or irinotecan alone, there was increased expression of IκBα following treatment with sorafenib and irinotecan. Lastly, following treatment with irinotecan and sorafenib irinotecan combination, there was decreased expression of p27Kip1 compared to sorafenib treatment alone.

TopI / pAKT / pMEK / pERK / p-p38 MAPK / pJNK2; 

PubMed: 29237470     


a Gimatecan significantly inhibited the expression of TopI, pAKT, pMEK, and pERK, and activated the expression of p-p38 MAPK and pJNK2 in SNU-1 cells. b Gimatecan significantly inhibited the expression of pAKT and pERK in NCI-N87 cells. Cells were starved in serum-free medium overnight, exposed to gimatecan or irinotecan for 48 h and harvested at 70–80% confluence. Total protein of SNU-1 and NCI-N87 was extracted and the expression of TopI, pAKT, pMEK, pERK, p-p38 MAPK and pJNK2 were assessed by western-blotting 

25973791 22206574 29237470
Immunofluorescence
NFκB; 

PubMed: 22206574     


BT12 cells were incubated with sorafenib or vehicle for 30 minutes followed by treatment with irinotecan for an additional 2 hours. For indirect immunofluorescence (A), cells were fixed and stained with antibodies to NF-κB followed by fluorescent labeled secondary antibodies. Concurrent DAPI stain was used to localize the nuclei (lower panel). Slides were visualized using a fluorescent microscope and random fields were photographed. The cytoplasmic staining seen in untreated and sorafenib treated cells was significantly reduced following treatment with irinotecan. However, the addition of sorafenib enabled the cells to maintain cytoplasmic staining in the presence of irinotecan. 

22206574
Growth inhibition assay
Cell viability; 

PubMed: 25973791     


The sensitivity of eight colon cancer cell lines to irinotecan was measured using the CCK-8 assay. For the CCK-8 assay, cells were exposed to irinotecan at given concentrations for 72 h before measurement. The cell viability was presented as the percentage relative to untreated cells.

25973791
In vivo In COLO 320 xenografts, Irinotecan induces a maximum growth inhibition of 92%. [5] A single dose of Irinotecan significantly increases amounts of topoisomerase I covalently bound to DNA in stomach, duodenum, colon and liver. Concomitantly, the Irinotecan-treated group shows significantly higher amounts of DNA strand breaks in colon mucosa cells compared to the control group. [6]

Protocol

Cell Research:

[1]

- Collapse
  • Cell lines: LoVo and HT-29 cells
  • Concentrations: 0 μM -100 μM
  • Incubation Time: 48 hours
  • Method:

    Exponentially growing cells (LoVo and HT-29 cells) are seeded in 20 cm2 Petri dishes with an optimal cell number for each cell line (2 × 104 for LoVo cells, 105 for HT-29 cells). They are treated 2 days later with increasing concentrations of Irinotecan or SN-38 for one cell doubling time (24 hours for LoVo cells, 40 hours for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the Irinotecan or SN-38 concentrations responsible for 50% growth inhibition as compared with cells incubated without Irinotecan or SN-38.


    (Only for Reference)
Animal Research:

[5]

- Collapse
  • Animal Models: Female nude mice with COLO 320 and WiDr xenografts.
  • Formulation: 0.9% NaCl
  • Dosages: 20 mg/kg
  • Administration: Intraperitoneal injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (147.67 mM)
Ethanol 7 mg/mL (10.33 mM)
Water 1 mg/mL (1.47 mM)
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5% DMSO+saline
For best results, use promptly after mixing.
20mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 677.18
Formula

C33H38N4O6.HCl.3H2O

CAS No. 136572-09-3
Storage powder
in solvent
Synonyms CPT-11 HCl Trihydrate

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04074343 Recruiting Drug: TAS-102|Drug: Irinotecan Gastric Adenocarcinoma|GastroEsophageal Cancer University of California Irvine|Taiho Pharmaceutical Co. Ltd. August 28 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Topoisomerase Signaling Pathway Map

Related Topoisomerase Products

Tags: buy Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate supplier | purchase Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate cost | Irinotecan HCl Trihydrate manufacturer | order Irinotecan HCl Trihydrate | Irinotecan HCl Trihydrate distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID